Ergotamine tartrate (sublingual tablet): Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
No edit summary
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
Line 35: Line 35:


==FDA Package Insert==
==FDA Package Insert==
==ERGOMAR (ergotamine tartrate) tablet==
'''  [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  indications and usage|Indications and Usage]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  dosage and administration|Dosage and Administration]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  contraindications|Contraindications]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  warnings and precautions|Warnings and Precautions]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  adverse reactions|Adverse Reactions]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  drug interactions|Drug Interactions]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  use in specific populations|Use in Specific Populations]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  overdosage|Overdosage]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  description|Description]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  clinical pharmacology|Clinical Pharmacology]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  clinical studies|Clinical Studies]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  patient counseling information|Patient Counseling Information]]'''
'''| [[ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert  labels and packages|Labels and Packages]]'''


'''  [[Ergotamine indications and usage|Indications and Usage]]'''
 
'''| [[Ergotamine dosage and administration|Dosage and Administration]]'''
==Medihaler ergotamine (ergotamine tartrate)==
'''| [[Ergotamine dosage forms and strengths|Dosage Forms and Strengths]]'''
 
'''| [[Ergotamine contraindications|Contraindications]]'''
'''  [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  indications and usage|Indications and Usage]]'''
'''| [[Ergotamine warnings and precautions|Warnings and Precautions]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  dosage and administration|Dosage and Administration]]'''
'''| [[Ergotamine adverse reactions|Adverse Reactions]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Ergotamine drug interactions|Drug Interactions]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  contraindications|Contraindications]]'''
'''| [[Ergotamine use in specific populations|Use in Specific Populations]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  warnings and precautions|Warnings and Precautions]]'''
'''| [[Ergotamine overdosage|Overdosage]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  adverse reactions|Adverse Reactions]]'''
'''| [[Ergotamine description|Description]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  drug interactions|Drug Interactions]]'''
'''| [[Ergotamine clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  use in specific populations|Use in Specific Populations]]'''
'''| [[Ergotamine nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  overdosage|Overdosage]]'''
'''| [[Ergotamine clinical studies|Clinical Studies]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  description|Description]]'''
'''| [[Ergotamine how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Ergotamine patient counseling information|Patient Counseling Information]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Ergotamine labels and packages|Labels and Packages]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  clinical studies|Clinical Studies]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  patient counseling information|Patient Counseling Information]]'''
'''| [[Medihaler ergotamine (ergotamine tartrate)® FDA Package Insert  labels and packages|Labels and Packages]]'''


==Mechanism of action==
==Mechanism of action==

Revision as of 02:28, 11 February 2014

Ergotamine
ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Medihaler ergotamine (ergotamine tartrate) aerosol, metered® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Medihaler ergotamine (ergotamine tartrate) aerosol, metered
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information about Ergotamine, click here.

Synonyms / Brand Names:

Overview

Ergotamine tartrate (sublingual tablet)
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Metabolismhepatic
Excretionrenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC33H35N5O5
Molar mass581.66 g/mol

Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for migraine prevention (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage.

Category

Anti Migraine Drugs

FDA Package Insert

ERGOMAR (ergotamine tartrate) tablet

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages


Medihaler ergotamine (ergotamine tartrate)

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of action

The mechanism of action of ergotamine is complex. The molecule shares similarity with neurotransmitters such as serotonin, dopamine, and adrenaline and can thus bind to several cell receptors acting both as agonist and antagonist in signal transduction within cellular tissues. The anti-migraine effect is due to constriction of the intercranial extracerebral blood vessels through the 5-HT1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT1D receptors. Ergotamine also has effects on the dopamine and noradrenaline receptors. It is its action on the D2 dopamine and 5-HT1A receptors that can cause some side effects. [1]

Biosynthesis

Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae. Its biosynthesis in these fungi requires the amino acid, L-tryptophan, and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, dimethylally-tryptophan (DMAT) synthase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.[2]

Illegal uses

Ergotamine is also a precursor of LSD, lysergic acid diethylamide.[3]


See also

References

  1. ↑ Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. PMID 10611116.
  2. ↑ Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. PMID 17133714.
  3. ↑ "ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS]". Retrieved 11 February 2014.

Template:Antimigraine preparations

da:Ergotamin de:Ergotamin nl:Ergotamine sv:Ergotamin


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Ergotamine_tartrate_(sublingual_tablet)&oldid=941778"